Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
NCT06760819Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of sevabertinib in solid tumor, sponsored by Bayer. Primary endpoint: Objective Response Rate. Started Feb 2025; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06760819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760819.